Old drug, new target. Ellipticines selectively inhibit RNA Polymerase I transcription. Andrews, W. J, Panova, T., Normand, C., Gadal, O., Tikhonova, I. G, & Panov, K. I The Journal of biological chemistry, 288(7):4567–4582, January, 2013. ![Old drug, new target. Ellipticines selectively inhibit RNA Polymerase I transcription. [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper doi abstract bibtex Transcription by RNA polymerase I (Pol-I) is the main driving force behind ribosome biogenesis, a fundamental cellular process that requires the coordinated transcription of all three nuclear polymerases. Increased Pol-I transcription, and the concurrent increase in ribosome biogenesis has been linked to the high rates of proliferation in cancers. The ellipticine family contains a number of potent anticancer therapeutic agents, some having progressed to stage І and II clinical trials; however, the mechanism by which many of the compounds work remains unclear. It has long been thought that inhibition of Top2 is the main reason behind the drugs antiproliferative effects. Here we report that a number of the ellipticines, including 9-Hydroxyellipticine (9HE), are potent and specific inhibitors of Pol-I transcription, with IC50 in vitro and in cells in the nanomolar range. Essentially, the drugs did not affect Pol-II and Pol-III transcription demonstrating a high selectivity. We have shown that Pol-I inhibition occurs by a p53, ATM/ATR and Top2 independent mechanism. We discovered that the drug influences the assembly and stability of pre-initiation complexes by targeting the interaction between promoter recognition factor SL1 and the rRNA promoter. Our findings will have an impact on the design and development of novel therapeutic agents specifically targeting ribosome biogenesis.
@article{Andrews2013,
title = {Old drug, new target. {Ellipticines} selectively inhibit {RNA} {Polymerase} {I} transcription.},
volume = {288},
issn = {1083-351X},
url = {http://www.ncbi.nlm.nih.gov/pubmed/23293027},
doi = {10.1074/jbc.M112.411611},
abstract = {Transcription by RNA polymerase I (Pol-I) is the main driving force behind ribosome biogenesis, a fundamental cellular process that requires the coordinated transcription of all three nuclear polymerases. Increased Pol-I transcription, and the concurrent increase in ribosome biogenesis has been linked to the high rates of proliferation in cancers. The ellipticine family contains a number of potent anticancer therapeutic agents, some having progressed to stage І and II clinical trials; however, the mechanism by which many of the compounds work remains unclear. It has long been thought that inhibition of Top2 is the main reason behind the drugs antiproliferative effects. Here we report that a number of the ellipticines, including 9-Hydroxyellipticine (9HE), are potent and specific inhibitors of Pol-I transcription, with IC50 in vitro and in cells in the nanomolar range. Essentially, the drugs did not affect Pol-II and Pol-III transcription demonstrating a high selectivity. We have shown that Pol-I inhibition occurs by a p53, ATM/ATR and Top2 independent mechanism. We discovered that the drug influences the assembly and stability of pre-initiation complexes by targeting the interaction between promoter recognition factor SL1 and the rRNA promoter. Our findings will have an impact on the design and development of novel therapeutic agents specifically targeting ribosome biogenesis.},
number = {7},
journal = {The Journal of biological chemistry},
author = {Andrews, William J and Panova, Tatiana and Normand, Christophe and Gadal, Olivier and Tikhonova, Irina G and Panov, Konstantin I},
month = jan,
year = {2013},
pmid = {23293027},
pages = {4567--4582},
}
Downloads: 0
{"_id":"s9sKxqMD7w7Q65K4Y","bibbaseid":"andrews-panova-normand-gadal-tikhonova-panov-olddrugnewtargetellipticinesselectivelyinhibitrnapolymeraseitranscription-2013","author_short":["Andrews, W. J","Panova, T.","Normand, C.","Gadal, O.","Tikhonova, I. G","Panov, K. I"],"bibdata":{"bibtype":"article","type":"article","title":"Old drug, new target. Ellipticines selectively inhibit RNA Polymerase I transcription.","volume":"288","issn":"1083-351X","url":"http://www.ncbi.nlm.nih.gov/pubmed/23293027","doi":"10.1074/jbc.M112.411611","abstract":"Transcription by RNA polymerase I (Pol-I) is the main driving force behind ribosome biogenesis, a fundamental cellular process that requires the coordinated transcription of all three nuclear polymerases. Increased Pol-I transcription, and the concurrent increase in ribosome biogenesis has been linked to the high rates of proliferation in cancers. The ellipticine family contains a number of potent anticancer therapeutic agents, some having progressed to stage І and II clinical trials; however, the mechanism by which many of the compounds work remains unclear. It has long been thought that inhibition of Top2 is the main reason behind the drugs antiproliferative effects. Here we report that a number of the ellipticines, including 9-Hydroxyellipticine (9HE), are potent and specific inhibitors of Pol-I transcription, with IC50 in vitro and in cells in the nanomolar range. Essentially, the drugs did not affect Pol-II and Pol-III transcription demonstrating a high selectivity. We have shown that Pol-I inhibition occurs by a p53, ATM/ATR and Top2 independent mechanism. We discovered that the drug influences the assembly and stability of pre-initiation complexes by targeting the interaction between promoter recognition factor SL1 and the rRNA promoter. Our findings will have an impact on the design and development of novel therapeutic agents specifically targeting ribosome biogenesis.","number":"7","journal":"The Journal of biological chemistry","author":[{"propositions":[],"lastnames":["Andrews"],"firstnames":["William","J"],"suffixes":[]},{"propositions":[],"lastnames":["Panova"],"firstnames":["Tatiana"],"suffixes":[]},{"propositions":[],"lastnames":["Normand"],"firstnames":["Christophe"],"suffixes":[]},{"propositions":[],"lastnames":["Gadal"],"firstnames":["Olivier"],"suffixes":[]},{"propositions":[],"lastnames":["Tikhonova"],"firstnames":["Irina","G"],"suffixes":[]},{"propositions":[],"lastnames":["Panov"],"firstnames":["Konstantin","I"],"suffixes":[]}],"month":"January","year":"2013","pmid":"23293027","pages":"4567–4582","bibtex":"@article{Andrews2013,\n\ttitle = {Old drug, new target. {Ellipticines} selectively inhibit {RNA} {Polymerase} {I} transcription.},\n\tvolume = {288},\n\tissn = {1083-351X},\n\turl = {http://www.ncbi.nlm.nih.gov/pubmed/23293027},\n\tdoi = {10.1074/jbc.M112.411611},\n\tabstract = {Transcription by RNA polymerase I (Pol-I) is the main driving force behind ribosome biogenesis, a fundamental cellular process that requires the coordinated transcription of all three nuclear polymerases. Increased Pol-I transcription, and the concurrent increase in ribosome biogenesis has been linked to the high rates of proliferation in cancers. The ellipticine family contains a number of potent anticancer therapeutic agents, some having progressed to stage І and II clinical trials; however, the mechanism by which many of the compounds work remains unclear. It has long been thought that inhibition of Top2 is the main reason behind the drugs antiproliferative effects. Here we report that a number of the ellipticines, including 9-Hydroxyellipticine (9HE), are potent and specific inhibitors of Pol-I transcription, with IC50 in vitro and in cells in the nanomolar range. Essentially, the drugs did not affect Pol-II and Pol-III transcription demonstrating a high selectivity. We have shown that Pol-I inhibition occurs by a p53, ATM/ATR and Top2 independent mechanism. We discovered that the drug influences the assembly and stability of pre-initiation complexes by targeting the interaction between promoter recognition factor SL1 and the rRNA promoter. Our findings will have an impact on the design and development of novel therapeutic agents specifically targeting ribosome biogenesis.},\n\tnumber = {7},\n\tjournal = {The Journal of biological chemistry},\n\tauthor = {Andrews, William J and Panova, Tatiana and Normand, Christophe and Gadal, Olivier and Tikhonova, Irina G and Panov, Konstantin I},\n\tmonth = jan,\n\tyear = {2013},\n\tpmid = {23293027},\n\tpages = {4567--4582},\n}\n\n","author_short":["Andrews, W. J","Panova, T.","Normand, C.","Gadal, O.","Tikhonova, I. G","Panov, K. I"],"key":"Andrews2013","id":"Andrews2013","bibbaseid":"andrews-panova-normand-gadal-tikhonova-panov-olddrugnewtargetellipticinesselectivelyinhibitrnapolymeraseitranscription-2013","role":"author","urls":{"Paper":"http://www.ncbi.nlm.nih.gov/pubmed/23293027"},"metadata":{"authorlinks":{}},"html":""},"bibtype":"article","biburl":"https://bibbase.org/zotero/eric.larG4","dataSources":["4i5C7S78DvJNsaHyg","5L2zM5wNE5CBYNuea"],"keywords":[],"search_terms":["old","drug","new","target","ellipticines","selectively","inhibit","rna","polymerase","transcription","andrews","panova","normand","gadal","tikhonova","panov"],"title":"Old drug, new target. Ellipticines selectively inhibit RNA Polymerase I transcription.","year":2013}